Table 1.
Study | Type | N | Stage | Statins | Recurrence | ||
---|---|---|---|---|---|---|---|
Kwan et al12 | Prospective | 1,945 | I–IIIA | Lipophilic (97.8%) | RR | 95% CI | |
Hydrophilic (2.2%) | >100 days | 0.67 | 0.39–1.13 | ||||
>2 years | 0.38 | 0.12–1.19 | |||||
Ahern et al13 | Prospective | 18,769 | I–III | Lipophilic (77.6%), simvastatin (71.7%) | HR | 95% CI | |
Hydrophilic (22.3%) | 5-Year lipophilic | 0.7 | 0.53–0.92 | ||||
5-Year simvastatin | 0.62 | 0.46–0.84 | |||||
5-Year hydrophilic | 1.1 | 0.7–1.80 | |||||
10-Year lipophilic | 0.73 | 0.6–0.89 | |||||
10-Year simvastatin | 0.7 | 0.57–0.86 | |||||
10-Year hydrophilic | 1.2 | 0.79–1.7 | |||||
Chae et al15 | Retrospective | 703 | II–III | Lipophilic (87.6%), atorvastatin (60.2%) | HR | 95% CI | |
Hydrophilic (12.4%) | Statins only | 0.4 | 0.24–0.67 | ||||
Statins + ACEi/ARBs | 0.3 | 0.15–0.61 | |||||
Boudreau et al16 | Prospective | 4,216 | I–IIB | Lipophilic, simvastatin (60.39%), fluvastatin (49.34%) | HR | 95% CI | |
Hydrophilic (3.63) | <1 year | 0.94 | 0.51–1.75 | ||||
1–2.9 years | 0.66 | 0.34–1.30 | |||||
3+ years | 0.77 | 0.42–1.41 | |||||
Trend | 0.89 | 0.74–1.08 | |||||
Sakellakis et al17 | Retrospective | 610 | I–III | Lipophilic (64%), atorvastatin (45%) | HR | 95% CI | |
Hydrophilic (16%) | All statin users | 0.58 | 0.36–0.94 | ||||
Brewer et al18 | Retrospective | 73 | III (IBC) | Lipophilic (39.7%) | HR | 95% CI | |
Hydrophilic (60.3%) | Hydrophilic only | 0.49 | 0.28–0.84 | ||||
Lacerda et al39 | Retrospective | 53 | III (IBC) | HR | 95% CI | ||
All statin users | 0.4 | 0.16–1.00 | |||||
Manthravadi et al14 | Meta-analysis | 75,684; 14 studies | I–IV | All | HR | 95% CI | |
All statins (10 studies) | 0.64 | 0.53–0.79 | |||||
Lipophilic (three studies) | 0.72 | 0.59–0.89 | |||||
Hydrophilic (three studies) | 0.8 | 0.44–1.46 |
Abbreviations: ACEi, angiotensin-converting enzyme inhibitors; ARBs, angiotensin receptor blockers; CI, confidence interval; HR, hazard ratio; IBC, inflammatory breast cancer; N, number; RR, relative risk.